Joel A Sincavage

Array ( [id] => 14566885 [patent_doc_number] => 20190211049 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-11 [patent_title] => ANTISENSE NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 16/359213 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16558 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16359213 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17287216 [patent_doc_number] => 11203757 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-21 [patent_title] => Use of Rad18 inhibitors in the treatment of tumors [patent_app_type] => utility [patent_app_number] => 16/297181 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 9641 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16297181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15557435 [patent_doc_number] => 20200063129 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => THERAPEUTIC ALTERATION OF TRANSPLANTABLE TISSUES THROUGH IN SITU OR EX VIVO EXPOSURE TO RNA INTERFERENCE MOLECULES [patent_app_type] => utility [patent_app_number] => 16/296530 [patent_app_country] => US [patent_app_date] => 2019-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16296530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14407543 [patent_doc_number] => 20190169615 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => MODULATION OF BCL11A FOR TREATMENT OF HEMOGLOBINOPATHIES [patent_app_type] => utility [patent_app_number] => 16/275534 [patent_app_country] => US [patent_app_date] => 2019-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16275534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17213183 [patent_doc_number] => 20210346519 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => HYBRID REGULATORY ELEMENTS [patent_app_type] => utility [patent_app_number] => 16/968196 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21977 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16968196 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16824605 [patent_doc_number] => 20210139898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-13 [patent_title] => STRUCTURAL DOMAINS OF ANTISENSE RNA MOLECULES UP-REGULATING TRANSLATION [patent_app_type] => utility [patent_app_number] => 16/967254 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12064 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16967254 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16939888 [patent_doc_number] => 11052103 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-06 [patent_title] => Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/267615 [patent_app_country] => US [patent_app_date] => 2019-02-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 61085 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267615 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14743835 [patent_doc_number] => 20190255091 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 16/267194 [patent_app_country] => US [patent_app_date] => 2019-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44251 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -59 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16267194 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16619897 [patent_doc_number] => 20210038550 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-11 [patent_title] => DISEASE DETECTION AND TREATMENT BASED ON TRIMETHYL-LYSINE LEVELS [patent_app_type] => utility [patent_app_number] => 16/965629 [patent_app_country] => US [patent_app_date] => 2019-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965629 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17921653 [patent_doc_number] => 11464874 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-10-11 [patent_title] => Treating metastatic cancer and model systems for metastatic disease [patent_app_type] => utility [patent_app_number] => 16/263677 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 59 [patent_figures_cnt] => 74 [patent_no_of_words] => 12608 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14403945 [patent_doc_number] => 20190167816 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-06-06 [patent_title] => METHODS FOR PREVENTING OR TREATING FIBROTIC DISEASES [patent_app_type] => utility [patent_app_number] => 16/263406 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15786 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16263406 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14868631 [patent_doc_number] => 20190284557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-19 [patent_title] => DOSAGES AND METHODS FOR DELIVERING LIPID FORMULATED NUCLEIC ACID MOLECULES [patent_app_type] => utility [patent_app_number] => 16/261181 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52873 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261181 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14778615 [patent_doc_number] => 20190264205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => Photoreversible Acylation Reagents [patent_app_type] => utility [patent_app_number] => 16/261422 [patent_app_country] => US [patent_app_date] => 2019-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17049 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -53 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16261422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17664177 [patent_doc_number] => 11357853 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Inhibition of a lncRNA for treatment of neuroblastoma [patent_app_type] => utility [patent_app_number] => 16/965876 [patent_app_country] => US [patent_app_date] => 2019-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 34 [patent_figures_cnt] => 37 [patent_no_of_words] => 7603 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16965876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14994361 [patent_doc_number] => 20190316138 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-17 [patent_title] => OLIGONUCLEOTIDE COMPOSITIONS WITH ENHANCED EFFICIENCY [patent_app_type] => utility [patent_app_number] => 16/253180 [patent_app_country] => US [patent_app_date] => 2019-01-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22219 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16253180 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18526475 [patent_doc_number] => 11713463 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-08-01 [patent_title] => Compositions and methods for increasing expression of SCN2A [patent_app_type] => utility [patent_app_number] => 16/962796 [patent_app_country] => US [patent_app_date] => 2019-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10896 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16962796 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15102661 [patent_doc_number] => 10472632 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-11-12 [patent_title] => Anti-connexin compounds targeted to connexins and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/241943 [patent_app_country] => US [patent_app_date] => 2019-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 17 [patent_no_of_words] => 34235 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15210457 [patent_doc_number] => 20190367915 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => Method for Assaying MicroRNA, Cancer Therapeutic Agent, and Medical Composition Containing Same for Cancer Therapy [patent_app_type] => utility [patent_app_number] => 16/241269 [patent_app_country] => US [patent_app_date] => 2019-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14489 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16241269 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14227067 [patent_doc_number] => 20190125706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-02 [patent_title] => TREATMENT AND DIAGNOSIS OF COLON CANCER [patent_app_type] => utility [patent_app_number] => 16/240123 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20362 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16240123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14897565 [patent_doc_number] => 20190292548 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-09-26 [patent_title] => Methods Of Identifying And Treating Poor-Prognosis Cancers [patent_app_type] => utility [patent_app_number] => 16/230098 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41323 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16230098 [rel_patent_id] =>[rel_patent_doc_number] =>)